Need Help?

Somatic L1 retrotransposition mapping in high-grade serous ovarian carcinoma using LDI-PCR/Nanopore-sequencing

Somatic L1 retrotransposition was mapped in high-grade serous carcinoma (HGSC) tumors using LDI-PCR/Nanopore-seq method. This method identifies somatic L1 insertions originating from two active L1 loci at chr22q12.1 and chrXp22.2. Multiple tumors from the same patient were utilised to understand L1-mediated intrapatient heterogeneity. Long-read data generated by LDI-Nanopore sequencing was aligned to the reference genome (GRCh38).

Request Access

DUO:0000007
version: 2019-01-07

disease specific research

This data use permission indicates that use is allowed provided it is related to the specified disease.

ModifiersMONDO:0004992

DUO:0000026
version: 2019-01-07

user specific restriction

This data use modifier indicates that use is limited to use by approved users.

DUO:0000027
version: 2019-01-07

project specific restriction

This data use modifier indicates that use is limited to use within an approved project.

DUO:0000028
version: 2019-01-07

institution specific restriction

This data use modifier indicates that use is limited to use within an approved institution.

The data can only be used for cancer research that is inline with the research areas delineated in the patient consent. These include cancer biomarkers, prognostic factors, mechanisms behind the tumor evolution during treatment and treatment options. The data can also be used for validation of studies published by the contributing consortia (MUPETFaasi2, HERCULES, CHEMORESPONSE).

The data can only be used for cancer research that is inline with the research areas delineated in the patient consent. These include cancer biomarkers, prognostic factors, mechanisms behind the tumor evolution during treatment and treatment options. The data can also be used for validation of studies published by the contributing consortia (MUPETFaasi2, HERCULES, CHEMORESPONSE). See link for full description

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS50000001198 Cancer Genomics

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Quality Report
Located in
EGAF00008740447 bam 368.8 MB
EGAF00008740448 bam 517.4 MB
EGAF00008740449 bam 133.4 MB
EGAF00008740450 bam 723.9 MB
EGAF00008740452 bam 293.3 MB
EGAF00008740453 bam 344.7 MB
EGAF00008740454 bam 303.0 MB
EGAF00008740455 bam 308.8 MB
EGAF00008740456 bam 927.3 MB
EGAF00008740457 bam 676.5 MB
EGAF00008740458 bam 364.5 MB
EGAF00008740459 bam 890.5 MB
EGAF00008740460 bam 740.0 MB
EGAF00008740461 bam 722.0 MB
EGAF00008740462 bam 635.5 MB
EGAF00008740463 bam 322.7 MB
EGAF00008740464 bam 881.8 MB
EGAF00008740465 bam 877.9 MB
EGAF00008740466 bam 527.0 MB
EGAF00008740467 bam 624.5 MB
EGAF00008740468 bam 267.5 MB
EGAF00008740469 bam 627.2 MB
EGAF00008740470 bam 237.6 MB
EGAF00008740471 bam 634.4 MB
EGAF00008740472 bam 460.1 MB
EGAF00008740473 bam 751.4 MB
EGAF00008740474 bam 295.4 MB
EGAF00008740475 bam 609.4 MB
EGAF00008740476 bam 660.8 MB
EGAF00008740477 bam 394.5 MB
EGAF00008740478 bam 222.7 MB
EGAF00008740479 bam 193.6 MB
EGAF00008740480 bam 429.0 MB
EGAF00008740481 bam 398.9 MB
EGAF00008740482 bam 302.4 MB
EGAF00008740483 bam 344.3 MB
EGAF00008740484 bam 344.1 MB
EGAF00008740485 bam 600.8 MB
EGAF00008740486 bam 686.3 MB
EGAF00008740487 bam 524.6 MB
EGAF00008740488 bam 352.3 MB
EGAF00008741586 bam 565.9 MB
EGAF00008741587 bam 608.1 MB
EGAF00008741588 bam 303.1 MB
EGAF00008741589 bam 640.4 MB
EGAF00008741590 bam 303.0 MB
EGAF00008741591 bam 673.1 MB
EGAF00008741592 bam 281.6 MB
EGAF00008741593 bam 328.0 MB
49 Files (24.2 GB)